GlassScriptPhysician profile
Miladys A Santos
NPI 1780864355
$17,719.21
in general payments reported to CMS, 2019-2025
33 companies · $2,560 in 2025
The $2,560 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,155 · 2022: $5,669 · 2023: $3,443 · 2024: $2,893 · 2025: $2,560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,895.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,204.36 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $3,478.30 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,437.69 | 2021-2025 | Jardiance, Synjardy, Ofev |
| Novo Nordisk INC | $1,269.49 | 2021-2025 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $907.87 | 2021-2025 | Xifaxan, Trulance |
| Amgen INC. | $882.43 | 2021-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $840.87 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $615.31 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $550.65 | 2021-2025 | Nexletol |
| Amarin Pharma, INC. | $539.53 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $508.75 | 2021-2023 | Xarelto |
| Ardelyx, INC. | $489.50 | 2024-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $465.98 | 2021-2023 | Verquvo, Belsomra |
| Ironwood Pharmaceuticals, INC | $356.42 | 2021-2025 | Linzess |
| Sumitomo Pharma America, INC. | $182.67 | 2024-2025 | Gemtesa |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $142.60 | 2021-2024 | Kristalose |
| Kowa Pharmaceuticals America, INC. | $142.55 | 2021-2025 | Zoryve, Livalo, Seglentis |
| Novartis Pharmaceuticals Corporation | $100.17 | 2022-2025 | |
| Intra-Sana Laboratories | $93.29 | 2023-2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Otsuka America Pharmaceutical, INC. | $74.66 | 2023-2025 | Rexulti |
| Insmed, INC. | $74.54 | 2024-2025 | Arikayce, Brinsupri |
| Pfizer INC. | $60.00 | 2023-2024 | |
| Axsome Therapeutics, INC. | $45.04 | 2025 | Auvelity |
| Hologic Sales and Service, LLC | $39.88 | 2025 | Aptima, Thinprep 2000 Processor |
| Genentech USA, INC. | $35.80 | 2021-2022 | |
| Abbott Laboratories | $28.13 | 2024 | Freestyle Libre 3 |
| Mirum Pharmaceuticals, INC. | $25.66 | 2024 | Cholbam |
| Scilex Pharmaceuticals INC. | $24.55 | 2023 | Ztlido |
| Sanofi-Aventis U.S. LLC | $22.62 | 2021 | |
| Philips North America LLC | $20.68 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.18 | 2025 | Caplyta |
| Incyte Corporation | $20.08 | 2025 | Opzelura |
| Global Blood Therapeutics, INC. | $18.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miladys Santos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.